Question Bank › New business is being written on visibly better

New business is being written on visibly better terms than the company's own recent norm, and the mix shift…

New business is being written on visibly better terms than the company's own recent norm, and the mix shift has just beg

Calls Tested
496
Answered YES
13
Hit Rate
2.6%
rare by design

Adaptive Biotechnologies Corporation (ADPT) — this company's answers

NO on the Q4 2022 call 2023-02-14 C+
The model's full reasoning — Q4 2022 call → NOWe need answer YES or NO. Need analyze transcript. Question asks: Does management indicate that economic terms of company's newest business — prices, rates, fees, spreads, contract sizes, durations, profitability at which most recent deals/orders/contracts/renewals are being struck — have stepped up meaningfully above company's own recent norm, and that improvement has only begun to flow into reported results because most business in reported numbers still written at older less favorable terms? Need use only transcript. Need identify if management says both halves. Transcript: Adaptive Biotechnologies. MRD clonoSEQ volumes, ASP. They mention ASP nearly $1,100 per test and expect it to continue to grow annually in mid-single digit. As finalize pricing agreements with non-contracted payers and improved collection performance. Also MRD pharma partnerships revenue growing. They guide 2023: MRD estimates include over 50% growth in clonoSEQ test volumes and continued ASP increase in mid-single digit range. Also milestones. They mention ASP growth trend towards $1700 per test over next few years. "We continue to invest in getting additional pricing agreements with non-contracted payers... improving collection performance... going after expanded coverage for new indications like DLBCL... expect ASP to grow steadily towards 1700 in next few years." This is about ASP increasing. Is that "new business terms" improved? They say ASP is nearly $1,100 per test and expect it to continue to grow annually in mid-single digit. This is achieved? They have pricing agreements. But is it "meaningfully above company's own recent norm"? Mid-single digit growth is not "meaningfully" step-up? Also "reported results still mostly reflect old terms"? They say "We anticipate ASP to continue to grow annually in mid-single digit" and "trend towards $1700 per test" over next few years. That implies future improvement, not already achieved? They say "ASP of 1100 ramped up faster than modeling" in analyst question. Management says "we've seen steady ASP growth over past couple years and anticipate that growth to continue in mid-single digit range over next two to three years and trend towards $1700." This is about pricing improving gradually.

← Back to the full ADPT analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management indicate that the ECONOMIC TERMS OF THE COMPANY'S NEWEST BUSINESS — the prices, rates, fees, spreads, contract sizes, durations, or profitability at which its most recent deals, orders, contracts, renewals, or transactions are being struck — have stepped up MEANINGFULLY ABOVE THE COMPANY'S OWN RECENT NORM, and that this improvement in the terms of incoming business has only BEGUN to flow into the reported results, because most of the business in the reported numbers was still written at the older, less favorable terms? Answer YES when management's own words convey BOTH halves of this one phenomenon, in whatever form fits the industry: (1) THE TERMS OF NEW BUSINESS HAVE VISIBLY IMPROVED VERSUS THE COMPANY'S OWN RECENT PAST. Management describes the transactions the company is signing, booking, or renewing NOW as carrying meaningfully better economics than what the same kind of business fetched in the company's own recent experience — for example: new contracts, charters, leases, policies, loans, or engagements being written at higher rates, prices, or spreads than those they replace; renewals or repeat orders coming in at clearly better levels than the expiring ones; recent deals notably larger, longer, or richer than the company's own norm; or the profitability of newly won work described as a step above the book it is joining. The comparison must be against the company's OWN recent terms (not against competitors or the industry), and the better terms must be described as ACTUALLY BEING ACHIEVED on real, current transactions — signed, booked, or closed — not merely targeted, quoted, hoped for, or dependent on future market moves. (2) THE REPORTED RESULTS STILL MOSTLY REFLECT THE OLD TERMS. Management conveys, directly or plainly in substance, that the improvement is early in the numbers: the reported period is still dominated by business struck at the earlier terms, the better-terms transactions are only a small or growing share of the mix, or results are expected to improve as the newer terms naturally become a larger portion of the business over coming periods — without requiring new demand, market recovery, or events not yet secured. Answer NO if better pricing is described mainly as passing through the company's own cost increases (inflation, freight, materials, wages, currency) rather than a genuine step-up in the economics of the business. NO if improved terms are only planned, targeted, quoted, or expected from future market conditions rather than already achieved on real transactions. NO if management describes pricing or terms as flat, competitive, under pressure, or deteriorating. NO if the improvement is attributed chiefly to a one-time deal, a temporary spike, or conditions management itself expects to reverse. NO if the better terms are already fully reflected in the reported results, with no meaningful mix shift still ahead. NO if the idea appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CTO CTO Realty Growth, Inc. Q2 2023 2023-07-28 B
CARS Cars.com Inc. Q1 2023 2023-05-06 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
FLR Fluor Corporation Q2 2022 2022-08-05 D
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
BRKL Brookline Bancorp, Inc. Q2 2022 2022-07-30 B+
INVH Invitation Homes Inc. Q2 2022 2022-07-28 B+
MTB M&T Bank Corporation Q2 2022 2022-07-20 B+
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
GNK Genco Shipping & Trading Limited Q2 2021 2021-08-07 A
ESS Essex Property Trust, Inc. Q2 2018 2018-08-03 B+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+

How the model reasoned

CRL · Q2 2022 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management's comments on Safety Assessment pricing and backlog directly address both required elements: they describe current bookings and backlog at "escalating prices" and "meaningful price increases" that are already achieved on real transactions (not targets or future expectations), while noting that the reported Q2 results are still dominated by older 2022 terms and that the stronger pricing is accelerating into H2 and 2023 bookings.
ESS · Q2 2018 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management describes the loss-to-lease metric rising to 3.
CTO · Q2 2023 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...

More from the question bank

Quarter of firsts: the period's story is buiPriced for one buyer, wanted by manyAlready inside the gateCostly self-restriction to protect one part Losses shrinking while the business growsUncontested runwayAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.